Physician profile
Benjamin Guidry
NPI 1770807315
$8,728.53
in general payments reported to CMS, 2019-2025
31 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $185 · 2021: $1,961 · 2022: $1,381 · 2023: $1,910 · 2024: $1,154 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,440.91 | 2019-2023 | Iluvien |
| Regeneron Healthcare Solutions, INC. | $1,003.33 | 2021-2025 | Eylea Hd, Eylea |
| Coherus Oncology, INC. | $626.22 | 2023-2024 | |
| Genentech USA, INC. | $445.24 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $399.91 | 2022-2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $394.17 | 2022-2025 | Eylea Hd |
| Bausch & Lomb Americas INC. | $331.16 | 2022-2025 | Miebo, Stellaris, Xiidra |
| Astellas Pharma US INC | $328.03 | 2023-2025 | Izervay |
| Eyepoint US, INC. | $320.30 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $294.66 | 2019-2020 | |
| Harrow Eye, LLC | $232.23 | 2023-2024 | Iheezo |
| Mallinckrodt Hospital Products INC. | $225.13 | 2022-2025 | Acthar |
| Sandoz INC. | $198.56 | 2024-2025 | Cimerli |
| Abbvie INC. | $182.74 | 2022-2024 | |
| Alcon Vision LLC | $156.59 | 2021-2025 | Clareon Panoptix Pro, Centurion |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $153.81 | 2024 | |
| Dompe US, INC. | $149.55 | 2024-2025 | Oxervate |
| Amgen INC. | $124.50 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $121.83 | 2025 | Xdemvy |
| Biogen, INC. | $120.05 | 2023-2024 | Byooviz |
| Spark Therapeutics, INC. | $114.75 | 2019 | |
| Allergan, INC. | $96.01 | 2019-2021 | |
| Optos, INC. | $73.85 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $39.71 | 2020-2023 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.56 | 2020 | |
| Janssen Biotech, INC. | $30.61 | 2022 | |
| Shire North American Group INC | $23.38 | 2019 | |
| Biotissue Holdings INC. | $20.71 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $16.29 | 2020 | |
| Beaver-Visitec International, INC. | $7.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.